Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RNAZ stock hub

TransCode Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RNAZis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

6.7M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RNAZ

In the news

Latest news · RNAZ

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-46.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-16

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RNAZ market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001829635
Company name	TransCode Therapeutics, Inc.
Country	United States
Country code	US
Cusip	89357L501
Employees	12
Employees Change	5%
Employees Change Percent	71.43
Enterprise value	$-11.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-07-09
Isin	US89357L5012
Last refreshed	2026-05-10
Market cap	$6.7M
Market cap category	Nano-Cap
Price	$7.32
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	RNAZ
Website	https://www.transcodetherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-540.38%
FCF yield	-290.86%
P/B ratio	0.65x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-36.3M
Net Income Growth Years	0%
Profit Per Employee	$-3M
ROA	-14.14
Roa5y	-93.96
ROCE	-12.08
ROE	-46.26
ROIC	-16

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-26.42%
Cagr3y	-96.86%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$162.4M
Cash	$17.8M
Current Assets	$22M
Current Liabilities	$3.5M
Equity	$151.9M
Interest Coverage	-2,901
Liabilities	$10.5M
Long Term Assets	$140.4M
Long Term Liabilities	$7M
Net Cash	$17.8M
Net Cash By Market Cap	$265
Net Cash Growth	208.58%
Net Debt Equity	$-0.12
Tangible Book Value	$-129.7M
Tangible Book Value Per Share	$-141
WACC	11.96

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.29
Net Working Capital	$676,124
Quick ratio	5.37
Working Capital	$18.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5,392.22%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-26.4%
200-day SMA	9.87
3Y total return	-100%
50-day SMA	8.86
50-day SMA vs 200-day SMA	50under200
All Time High	5,174,453
All Time High Change	-100%
All Time High Date	2021-07-09
All Time Low	6.08
All Time Low Change	20.34%
All Time Low Date	2025-12-29
ATR	0.57
Beta	1.4
Beta1y	0.09
Beta2y	2.79
Ch YTD	7.17
High	8.01
High52	20.99
High52 Date	2025-10-08
High52ch	-65.13%
Low	7.3
Low52	6.08
Low52 Date	2025-12-29
Low52ch	20.34%
Ma50ch	-17.38%
Price vs 200-day SMA	-25.87%
RSI	30.16
RSI Monthly	22.65
RSI Weekly	29.53
Sharpe ratio	-0.09x
Sortino ratio	-0.08
Total Return	-5,392.22%
Tr YTD	7.17
Tr1m	-15.86%
Tr1w	-6.51%
Tr3m	-17.85%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-19.2M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	832,425%
Float Percent	90.78%
Shares Insiders	0.14%
Shares Institutions	5.78%
Shares Out	916,968
Shares Qo Q	9.52%
Shares Yo Y	5,392.22%
Short Float	4.93%
Short Ratio	5.5
Short Shares	4.48

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-20M
Average Volume	6,752.95x
Bv Per Share	11.27
CAPEX	$-6,660
Ch1m	-15.86
Ch1w	-6.51
Ch1y	-26.4
Ch3m	-17.85
Ch3y	-100
Ch6m	-22.39
Change	-4.31%
Change From Open	-2.27
Close	7.65
Days Gap	-2.09
Depreciation Amortization	76,446
Dollar Volume	50,888.6
Earnings Date	2026-04-15
Earnings Time	amc
EBIT	$-19.2M
EBITDA	$-19.1M
EPS	$-52.59
F Score	2
FCF	$-19.5M
FCF EV Yield	175.86x
FCF Per Share	$-21.29
Financing CF	31,523,122
Fiscal Year End	December
Founded	2,016
Goodwill	25,744,143
Income Tax	$226,068
Investing CF	-4,436
Ipr	83
Iprfo	-100
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-15
Last Report Date	2025-12-31
Last Split Date	2025-05-15
Last Split Type	Reverse
Last10k Filing Date	2026-04-15
Ma150	9.56
Ma150ch	-23.41%
Ma20	8.33
Ma20ch	-12.15%
Net CF	12,002,457
Next Earnings Date	2026-08-16
Open	7.49
Optionable	No
Position In Range	2.82
Post Close	7.32
Postmarket Change Percent	0.55
Postmarket Price	$7.36
Ppne	370,681
Price Date	2026-05-08
Relative Volume	1.03x
Share Based Comp	485,428
Tr6m	-22.39%
Us State	Massachusetts
Volume	6,952

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RNAZ pay a dividend?

Capital-return profile for this ticker.

Performance

RNAZ stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RNAZ?

Insider, institutional, and short-interest positioning.

Institutional ownership

+5.8%

Float: +90.8% of shares outstanding

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RNAZ momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

30.2

Neutral momentum band

Price vs 200-day MA

-25.9%

50/200-day relationship not available

Beta (5Y)

1.40

More volatile than the market

Sharpe ratio

-0.09

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RNAZ

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RNAZ stock rating?

TransCode Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RNAZ analysis?

The full report lives at /stocks/RNAZ/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RNAZ?

The latest report frames RNAZ around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RNAZ page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.